Home About Us Pipeline News Investors Contacts Careers

STOCK INFORMATION

UPCOMING EVENTS

There are no scheduled events at this time. Please check back later.

FEATURED PRESS RELEASE

  • 5/18/16 2:05 pm PDT
    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3–7, 2016, in Chicago. Abstracts are available to the public online on the ASCO website: www.abstract.asco.org. Abstract #516: Phase II Trial of Neratinib for HER2 Mutated,more...

SEARCH INVESTOR RELATIONS

CONTACTS

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

ir@pumabiotechnology.com